Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against REGENXBIO ...
Eagletribune
Gainey McKenna & Egleston filed a class action lawsuit against REGENXBIO alleging false and misleading statements regarding its RGX-111 trial.Summary
Gainey McKenna & Egleston announced a securities class action lawsuit filed in the United States District Court for the District of Maryland against REGENXBIO Inc. (NASDAQ: RGNX). The lawsuit concerns purchases of REGENXBIO securities between February 9, 2022, and January 27, 2026. The complaint alleges that the defendants made overly positive statements to investors while concealing adverse facts about the efficacy and safety of the RGX-111 trial study. Specifically, the lawsuit claims the truth emerged on January 28, 2026, when REGENXBIO announced the FDA placed a clinical hold on its RGX-111 investigational gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant.
(Source：Eagletribune)